Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer, marking a strategic shift aiming to expand its global market presence ...

The level of weight loss was similar to that achieved over the same period with Novo Nordisk’s injection but slightly lower than that with Eli Lilly’s injection in unrelated trials.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)'s share was trading ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Did Eli Lilly just say checkmate to Novo Nordisk? Well, an approval for an oral drug would represent a big victory. First, its likely many people would prefer a daily pill instead of an injection ...

What it means: Current GLP-1 drugs used for weight loss, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are administered via a once-per-week injection. A pill form of the drug could ...

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to ...